PROTAGONIST THERAPEU

PTGX
Delayed Quote. Delayed  - 12/02 04:00:00 pm
32.69USD +5.69%
Valuation
Fiscal Period: December 2020 2021
Capitalization1 8671 476
Entreprise Value (EV)1 5611 228
P/E ratio -10,5x-11,4x
Yield --
Capitalization / Revenue 30,3x61,9x
EV / Revenue 19,6x51,5x
EV / EBITDA -8,81x-9,10x
Price to Book --
Nbr of stocks (in thousands) 43 01947 728
Reference price (USD) 20,230,9
Announcement Date 03/10/2021-
Previous period Next period
1 USD in Million
Estimates
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2020 2021
Net sales1 28,623,8
EBITDA1 -63,7-135
Operating profit (EBIT)1 -64,5-127
Operating Margin -225%-532%
Pre-Tax Profit (EBT)1 -64,8-128
Net income1 -66,2-127
Net margin -231%-533%
EPS2 -1,92-2,71
Dividend per Share --
Announcement Date 03/10/2021-
Previous period Next period
1 USD in Million
2 USD
Finances - Leverage
Fiscal Period: December 2020 2021
Net Debt1 --
Net Cash position1 306248
Leverage (Debt / EBITDA) 4,80x1,84x
Free Cash Flow1 -73,0-86,0
ROE (Net Profit / Equities) -36,8%-47,4%
Shareholders' equity1 180268
ROA (Net Profit / Asset) -27,6%-39,0%
Assets1 240326
Book Value Per Share --
Cash Flow per Share --
Capex1 0,470,70
Capex / Sales 1,65%2,94%
Announcement Date 03/10/2021-
Previous period Next period
1 USD in Million
Financial Ratios
Size 2021e 2022e
Capitalization 1 476 M $ -
Entreprise Value (EV) 1 228 M $ 1 292 M $
Valuation 2021e 2022e
P/E ratio (Price / EPS) -11,4x -9,66x
Capitalization / Revenue 61,9x 55,5x
EV / Revenue 51,5x 46,2x
EV / EBITDA -9,10x -5,46x
Yield (DPS / Price) - -
Price to book (Price / BVPS) - -
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) -532% -605%
Operating Leverage (Delta EBIT / Delta Sales) -5,77x -
Net Margin (Net Profit / Revenue) -533% -627%
ROA (Net Profit / Asset) -39,0% -60,3%
ROE (Net Profit / Equities) -47,4% -78,2%
Rate of Dividend - -
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   2,94% 3,76%
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) 13,7x 10,4x
Financial Leverage (Net Debt / EBITDA) - -
EPS & Dividend